Endocrine Abstracts

According to the current WHO classification neuroendocrine neoplasias (NEN) are classified according to differentiation into well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). NEN are classified in addition to organ of origin and grade. More recent molecular data confirms this approach as the identified mutation spectrum differs according to differentiation and organ of origin. However, NEN might be more heterogeneous: Ex...

Neuroendocrine tumors do not share many classical pathways of tumorigenesis with their non-endocrine counterparts. In recent years, the molecular understanding of of pancreatic neuroendocrine tumors (PanNET) tumorigenesis has made major advances. A whole exome NGS analysis described frequent mutations of two new genes DAXX and ATRX. 40% of unselected panNET show mutations in one of these genes. Mutations in these genes are associated with loss of the respecti...

Introduction: Apart from occurring sporadically, insulinoma within the framework of multiple endocrine neoplasia 1 (MEN-1) is well known. The rare presence of multifocal insulinomas has recently been assigned a separate entity (insulinomatosis). The difficulty of localising insulinomas may be improved by GLP1-receptor imaging.Case report A 48-year-old woman had been treated for suspected epileptic seizures for 2 years (lamotrigine). During another such e...

Context: Surgical intervention is advised in patients with multiple endocrine neoplasia type-1 (MEN-1) with non-functioning pancreatic neuroendocrine tumors (PanNET) and a size ≥20 mm. However, functioning PanNET such as patients with endogenous hyperinsulinemic hypoglycemia (EHH) due to (one or multiple) insulinomas should be treated surgically independent of size. Reliable preoperative localization of insulinomas is critical for surgical strategy.<p class="abstext"...

Introduction: Medical therapy of Pancreatic neuroendocrine tumors (P-NETs) may take advantage from mammalian target of rapamycin (mTOR) inhibitors. However, so far, the extent of therapeutic response cannot be predicted.Aim: To investigate the possible predictors of sensitivity to mTOR inhibitors in P-NETs.Materials and methods: P-NET primary cultures were treated with IGF1 and/or Everolimus. Cell viability and caspase activity wer...

Endocrine-Related Cancer, 2022, 29(1), 1-14 (DOI: https://doi.org/10.1530/ERC-21-0152): ...